Starship National Air Ambulance life flight saves Christchurch boy born with heart condition
Starship National Air Ambulance life flight saves Christchurch boy born with heart condition
From Starship National Air breaking news to debate conversation.
"The PARTNER 3 Trial demonstrated that low-risk patients treated with the SAPIEN 3 TAVR experienced extraordinary outcomes with 1. 0 percent rates of death or disabling stroke at one year, a short length of stay and 96 percent discharged to home or self-care. SAPIEN 3 is the only valve to achieve superiority over surgery based on the prespecified primary endpoint," said Martin B. Leon, M. D. , director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Medical Center and critical aortic stenosis professor of medicine at the Columbia University College of Physicians and Surgeons. "Today's FDA approval of SAPIEN 3 TAVR will expand access to this proven therapy, which should be considered the preferred treatment for the majority of low-risk severe AS patients. " Leon is the national co-principal investigator of the PARTNER 3 Trial. The SAPIEN 3 TAVR's low-risk approval was based on data from the landmark PARTNER 3 Trial, an independently evaluated, randomized clinical trial comparing outcomes between TAVR and open-heart surgery.
“I really don’t even know I ‘I really did felt. I we would be this and I I would to those feelings of him back and not knowing to expect during Edwards SAPIEN 3 surgery,” Laura. .
Comments
Post a Comment